Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | FGFR2 rearrange |
Gene Variant Detail | |
Relevant Treatment Approaches | FGFR Inhibitor (Pan) FGFR2 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 rearrange FGFR2 amp | cholangiocarcinoma | predicted - sensitive | Futibatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Lytgobi (futibatinib) treatment resulted in partial response in a patient with cholangiocarcinoma harboring FGFR2 rearrangement and FGFR2 amplification (Annals of Oncology, Volume 29, Issue suppl_5). | detail... |
FGFR2 rearrange FGFR2 N550D FGFR2 N550H FGFR2 N550K FGFR2 N550T FGFR2 V565I FGFR2 V565L | cholangiocarcinoma | predicted - resistant | Pemigatinib | Case Reports/Case Series | Actionable | In a retrospective analysis, a cholangiocarcinoma patient harboring an FGFR2 rearrangement progressed on treatment with Pemazyre (pemigatinib) and was found to have acquired FGFR2 N550K, N550D, N550T, N550H, and V565I via cell-free DNA, and FGFR2 V565L via cell-free DNA and tissue biopsy (PMID: 39706336). | 39706336 |
FGFR2 rearrange NRAS Q61K | cholangiocarcinoma | predicted - resistant | Pemigatinib | Case Reports/Case Series | Actionable | In a retrospective analysis, a cholangiocarcinoma patient harboring an FGFR2 rearrangement progressed on treatment with Pemazyre (pemigatinib) and was found to have acquired NRAS Q61K via cell-free DNA (PMID: 39706336). | 39706336 |